CN108473952B - 使用经遗传矫正的自体角质形成细胞进行的隐性营养不良型大疱性表皮松解症的基因疗法 - Google Patents

使用经遗传矫正的自体角质形成细胞进行的隐性营养不良型大疱性表皮松解症的基因疗法 Download PDF

Info

Publication number
CN108473952B
CN108473952B CN201780005233.2A CN201780005233A CN108473952B CN 108473952 B CN108473952 B CN 108473952B CN 201780005233 A CN201780005233 A CN 201780005233A CN 108473952 B CN108473952 B CN 108473952B
Authority
CN
China
Prior art keywords
sheet
pgcn
test
cells
copy number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780005233.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108473952A (zh
Inventor
祖拉布·希普拉什维利
尼贡·T·纽伦
M·皮特·马林科维奇
吉恩·唐
阿尔弗雷德·T·莱恩
保罗·A·卡瓦里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Veterans Affairs
Leland Stanford Junior University
Original Assignee
US Department of Veterans Affairs
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Veterans Affairs, Leland Stanford Junior University filed Critical US Department of Veterans Affairs
Priority to CN202210368934.5A priority Critical patent/CN114699558B/zh
Publication of CN108473952A publication Critical patent/CN108473952A/zh
Application granted granted Critical
Publication of CN108473952B publication Critical patent/CN108473952B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3695—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Manufacturing & Machinery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780005233.2A 2016-01-04 2017-01-03 使用经遗传矫正的自体角质形成细胞进行的隐性营养不良型大疱性表皮松解症的基因疗法 Expired - Fee Related CN108473952B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210368934.5A CN114699558B (zh) 2016-01-04 2017-01-03 使用经遗传矫正的自体角质形成细胞进行的隐性营养不良型大疱性表皮松解症的基因疗法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662274700P 2016-01-04 2016-01-04
US62/274,700 2016-01-04
US201662414533P 2016-10-28 2016-10-28
US62/414,533 2016-10-28
PCT/US2017/012061 WO2017120147A1 (en) 2016-01-04 2017-01-03 Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210368934.5A Division CN114699558B (zh) 2016-01-04 2017-01-03 使用经遗传矫正的自体角质形成细胞进行的隐性营养不良型大疱性表皮松解症的基因疗法

Publications (2)

Publication Number Publication Date
CN108473952A CN108473952A (zh) 2018-08-31
CN108473952B true CN108473952B (zh) 2022-04-08

Family

ID=58010360

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210368934.5A Expired - Fee Related CN114699558B (zh) 2016-01-04 2017-01-03 使用经遗传矫正的自体角质形成细胞进行的隐性营养不良型大疱性表皮松解症的基因疗法
CN201780005233.2A Expired - Fee Related CN108473952B (zh) 2016-01-04 2017-01-03 使用经遗传矫正的自体角质形成细胞进行的隐性营养不良型大疱性表皮松解症的基因疗法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210368934.5A Expired - Fee Related CN114699558B (zh) 2016-01-04 2017-01-03 使用经遗传矫正的自体角质形成细胞进行的隐性营养不良型大疱性表皮松解症的基因疗法

Country Status (17)

Country Link
US (4) US12173314B2 (enExample)
EP (2) EP3400287B1 (enExample)
JP (3) JP7159048B2 (enExample)
KR (1) KR20180093967A (enExample)
CN (2) CN114699558B (enExample)
AU (2) AU2017205925B2 (enExample)
BR (1) BR112018013576A2 (enExample)
CA (1) CA3008676A1 (enExample)
DK (1) DK3400287T3 (enExample)
ES (1) ES2861453T3 (enExample)
IL (2) IL260038B (enExample)
MX (1) MX2018007986A (enExample)
NZ (1) NZ743682A (enExample)
PT (1) PT3400287T (enExample)
RU (2) RU2021121824A (enExample)
WO (1) WO2017120147A1 (enExample)
ZA (1) ZA201803962B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3400287T3 (da) * 2016-01-04 2021-03-01 Univ Leland Stanford Junior Genterapi for recessiv dystrofisk epidermolysis bullosa under anvendelse af genetisk korrigerede autologe keratinocytter
IT201700094210A1 (it) * 2017-08-17 2019-02-17 Holostem Terapie Avanzate S R L Metodo per produrre lembi cellulari
IT201700104587A1 (it) * 2017-09-19 2019-03-19 Holostem Terapie Avanzate S R L Usi terapeutici di lembi di cellule geneticamente modificate
EP3733210A4 (en) * 2017-12-29 2021-10-06 Genemedicine Co., Ltd. CELL SHEET FOR GENE DELIVERY
RU2730661C2 (ru) * 2018-12-27 2020-08-24 Селл энд Джин Терапи Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-COL1A1, или Escherichia coli SCS110-AF/VTvaf17-COL1A2, или Escherichia coli SCS110-AF/VTvaf17-P4HA1, или Escherichia coli SCS110-AF/VTvaf17-P4HA2, или Escherichia coli SCS110-AF/VTvaf17-COL7A1, или Escherichia coli SCS110-AF/VTvaf17-CLCA2, или Escherichia coli SCS110-AF/VTvaf17-ELN, или Escherichia coli SCS110-AF/VTvaf17- PLOD1, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
WO2020149395A1 (ja) 2019-01-18 2020-07-23 国立大学法人大阪大学 栄養障害型表皮水疱症治療薬
CN116529361B (zh) * 2019-10-18 2024-01-26 北赛泓升(北京)生物科技有限公司 使用多顺反子sox2、klf4和任选的c-myc产生诱导多能干细胞
KR20230043906A (ko) * 2020-07-22 2023-03-31 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 영양 장애형 표피 수포증의 치료약
MX2024004434A (es) 2021-10-12 2024-07-09 Phoenix Tissue Repair Inc Terapia de reemplazo de proteínas con colágeno 7.
JP2025094280A (ja) * 2022-01-21 2025-06-25 国立大学法人大阪大学 細胞シート

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830725A (en) * 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US20020090725A1 (en) 2000-11-17 2002-07-11 Simpson David G. Electroprocessed collagen
NZ516897A (en) * 1999-07-02 2004-01-30 Human Genome Sciences Inc Polynucleotides and associated polypeptides for KGF-2 (also known as Fibroblast Growth Factor 12) to promote and accelerate internal and external wound healing
FR2857671B1 (fr) * 2003-07-18 2007-10-05 Centre Nat Rech Scient Nouveau procede de culture de keratinocytes et ses applications
CN1916166B (zh) * 2006-09-08 2010-08-11 北京赛尔泰和生物医药科技有限公司 自体角膜上皮的制备方法
US8865199B2 (en) * 2008-11-17 2014-10-21 Ingeneron, Inc. Biomatrix composition and methods of biomatrix seeding
GB201202561D0 (en) * 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
EP3995158A1 (en) * 2012-11-06 2022-05-11 Imbed Biosciences, Inc. Methods and compositions for wound healing
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN105087565A (zh) * 2015-08-21 2015-11-25 内蒙古自治区人民医院 一种营养不良型大疱性表皮松解症核苷酸及其应用
DK3400287T3 (da) * 2016-01-04 2021-03-01 Univ Leland Stanford Junior Genterapi for recessiv dystrofisk epidermolysis bullosa under anvendelse af genetisk korrigerede autologe keratinocytter
CA3017757A1 (en) * 2016-03-18 2017-09-21 Intrexon Corporation Compositions and methods for treatment of type vii collagen deficiencies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa;Vittorio Sebastiano1 et al;《Science Translational Medicine》;20141126;第6卷;第264ra163页 *
Phase I clinical trial of genetically corrected autologous epidermal keratinocytes for recessive dystrophic epidermolysis;Z Siprashvili et al;《Journal of Investigative Dermatology》;20141231;第134卷(第Suppl 1期);第S75页，摘要430 *

Also Published As

Publication number Publication date
US12110504B2 (en) 2024-10-08
ZA201803962B (en) 2023-01-25
ES2861453T3 (es) 2021-10-06
US12385010B2 (en) 2025-08-12
CN114699558A (zh) 2022-07-05
IL293465B1 (en) 2023-04-01
AU2020239779A1 (en) 2020-10-22
US20240067926A1 (en) 2024-02-29
US12173314B2 (en) 2024-12-24
IL260038A (enExample) 2018-07-31
DK3400287T3 (da) 2021-03-01
WO2017120147A1 (en) 2017-07-13
JP2024167419A (ja) 2024-12-03
EP3400287B1 (en) 2020-12-30
JP2019506925A (ja) 2019-03-14
KR20180093967A (ko) 2018-08-22
NZ743682A (en) 2020-01-31
RU2753248C2 (ru) 2021-08-12
JP7159048B2 (ja) 2022-10-24
RU2018127524A (ru) 2020-01-27
CA3008676A1 (en) 2017-07-13
RU2018127524A3 (enExample) 2020-01-27
AU2017205925A1 (en) 2018-07-12
US20190382724A1 (en) 2019-12-19
JP7555380B2 (ja) 2024-09-24
BR112018013576A2 (pt) 2018-12-11
CN108473952A (zh) 2018-08-31
EP3842520A1 (en) 2021-06-30
US20250075178A1 (en) 2025-03-06
IL293465B2 (en) 2023-08-01
AU2017205925B2 (en) 2020-10-15
MX2018007986A (es) 2018-11-09
IL260038B (en) 2022-07-01
EP3400287A1 (en) 2018-11-14
PT3400287T (pt) 2021-03-17
RU2021121824A (ru) 2021-08-18
CN114699558B (zh) 2023-07-28
US20250257319A1 (en) 2025-08-14
IL293465A (en) 2022-08-01
JP2023002634A (ja) 2023-01-10

Similar Documents

Publication Publication Date Title
CN108473952B (zh) 使用经遗传矫正的自体角质形成细胞进行的隐性营养不良型大疱性表皮松解症的基因疗法
KR101027755B1 (ko) 바이러스 생산용 불멸화된 조류 세포주
JP7215905B2 (ja) Ｖｉｉ型コラーゲン欠損症の治療のための組成物及び方法
US8470555B2 (en) Protein substance having triple helix structure and manufacturing method therefor
CA2319096C (en) Method for treating acute intermittent porphyria (aip) and other porphyric diseases
CA3199661A1 (en) Lysosomal acid lipase variants and uses thereof
HK40052811A (en) Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
RU2823437C2 (ru) Лечение и/или профилактика заболевания или синдрома, связанного с вирусной инфекцией
HK40000104B (en) Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
HK40000104A (en) Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
KR20230005965A (ko) 바이러스 감염 관련 질환 또는 증후군의 치료 및/또는 예방
HK1260451A1 (en) Compositions and methods for treatment of type vii collagen deficiencies
HK1260451B (en) Compositions and methods for treatment of type vii collagen deficiencies
HK1163153B (en) Protein substance having triple helix structure and manufacturing method therefor
HK1230218A (en) Protein substance having triple helix structure and manufacturing method therefor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220408

CF01 Termination of patent right due to non-payment of annual fee